AVN 63.60 Increased By ▲ 1.85 (3%)
BOP 8.65 Decreased By ▼ -0.08 (-0.92%)
CHCC 124.50 Decreased By ▼ -2.00 (-1.58%)
DCL 8.85 Decreased By ▼ -0.06 (-0.67%)
DGKC 101.70 Decreased By ▼ -0.56 (-0.55%)
EFERT 61.65 Decreased By ▼ -4.90 (-7.36%)
EPCL 42.99 Decreased By ▼ -0.26 (-0.6%)
FCCL 20.40 Decreased By ▼ -0.05 (-0.24%)
FFL 13.67 Increased By ▲ 0.08 (0.59%)
HASCOL 13.39 Decreased By ▼ -0.08 (-0.59%)
HBL 128.88 Increased By ▲ 0.38 (0.3%)
HUBC 79.40 Increased By ▲ 0.54 (0.68%)
HUMNL 7.10 Increased By ▲ 0.72 (11.28%)
JSCL 21.85 Increased By ▲ 0.02 (0.09%)
KAPCO 27.60 Increased By ▲ 0.11 (0.4%)
KEL 3.60 No Change ▼ 0.00 (0%)
LOTCHEM 11.75 Decreased By ▼ -0.03 (-0.25%)
MLCF 36.51 Decreased By ▼ -0.74 (-1.99%)
OGDC 93.80 Increased By ▲ 1.44 (1.56%)
PAEL 30.35 Decreased By ▼ -0.10 (-0.33%)
PIBTL 11.78 Decreased By ▼ -0.01 (-0.08%)
PIOC 83.35 Decreased By ▼ -1.50 (-1.77%)
POWER 9.20 Increased By ▲ 0.05 (0.55%)
PPL 84.45 Increased By ▲ 1.91 (2.31%)
PSO 187.55 Increased By ▲ 1.06 (0.57%)
SNGP 43.00 Increased By ▲ 0.50 (1.18%)
STPL 13.30 No Change ▼ 0.00 (0%)
TRG 51.33 Increased By ▲ 0.23 (0.45%)
UNITY 23.34 Increased By ▲ 0.04 (0.17%)
WTL 0.99 No Change ▼ 0.00 (0%)
BR100 4,131 Increased By ▲ 19.61 (0.48%)
BR30 20,689 Increased By ▲ 66.76 (0.32%)
KSE100 39,863 Increased By ▲ 230.84 (0.58%)
KSE30 16,752 Increased By ▲ 58.2 (0.35%)

Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).

“Our vaccine therefore costs about the same as a flu shot, which is between $10 and $50,” he was quoted as saying.

On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose.

“Nothing is signed yet, but we’re close to a deal with the EU Commission. We want to deliver to Europe and are in constructive talks,” Bancel told WamS, adding it was just a “matter of days” until a contract would be ready.

Moderna has said its experimental vaccine is 94.5% effective in preventing COVID-19, based on interim data from a late-stage clinical trial, becoming the second developer to report results that far exceeded expectations after Pfizer and its partner BioNTech.

The EU has been in talks with Moderna for its experimental COVID-19 vaccine at least since July.